Journey Medical Corp (DERM) - Total Liabilities
Based on the latest financial reports, Journey Medical Corp (DERM) has total liabilities worth $59.29 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DERM cash flow conversion to assess how effectively this company generates cash.
Journey Medical Corp - Total Liabilities Trend (2014–2024)
This chart illustrates how Journey Medical Corp's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Journey Medical Corp's assets to evaluate the company's liquid asset resilience ratio.
Journey Medical Corp Competitors by Total Liabilities
The table below lists competitors of Journey Medical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AMC Robotics Corporation
NASDAQ:AMCI
|
USA | $5.26 Million |
|
Merkur PrivatBank KgaA
XETRA:MBK
|
Germany | €3.65 Billion |
|
Iljin Diamond
KO:081000
|
Korea | ₩72.60 Billion |
|
Seoho Electric Co.Ltd
KQ:065710
|
Korea | ₩20.41 Billion |
|
Kyungin Synthe
KO:012610
|
Korea | ₩280.66 Billion |
|
Whitehawk Therapeutics, Inc.
NASDAQ:WHWK
|
USA | $9.85 Million |
|
Protech Mitra Perkasa Tbk PT
JK:OASA
|
Indonesia | Rp78.88 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Journey Medical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DERM market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Journey Medical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Journey Medical Corp (2014–2024)
The table below shows the annual total liabilities of Journey Medical Corp from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $60.17 Million | +6.50% |
| 2023-12-31 | $56.50 Million | -35.93% |
| 2022-12-31 | $88.18 Million | +59.62% |
| 2021-12-31 | $55.24 Million | +32.75% |
| 2020-12-31 | $41.61 Million | +33.78% |
| 2019-12-31 | $31.11 Million | -91.20% |
| 2018-12-31 | $353.36 Million | -14.05% |
| 2017-12-31 | $411.14 Million | +530.29% |
| 2016-12-31 | $65.23 Million | +78.93% |
| 2015-12-31 | $36.46 Million | +47.95% |
| 2014-12-31 | $24.64 Million | -- |
About Journey Medical Corp
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a top… Read more